Overview
Bruker Q3 2025 revenue of $860.5 mln beats analyst expectations despite a 0.5% yoy decline
Adjusted EPS for Q3 2025 beats consensus at $0.45, despite a decline from last year
Company lowers FY2025 guidance, citing weaker demand and EPS dilution from higher share count
Outlook
Bruker expects FY2025 revenue of $3.41 to $3.44 bln, with 1-2% growth yoy
Company forecasts FY2025 non-GAAP EPS of $1.85 to $1.90
Bruker anticipates significant margin expansion and EPS growth in FY2026
Result Drivers
BOOKINGS GROWTH - Mid-single digit percentage organic bookings growth driven by academic/government and biopharma markets
PRODUCT RECEPTION - New spatial biology and proteomics solutions well-received by biopharma and academic customers
DEMAND WEAKNESS - Revenue decline due to weaker academic and research instruments demand in H1 2025
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q3 Revenue | Beat | $860.50 mln | $848.72 mln (12 Analysts) |
Q3 Adjusted EPS | Beat | $0.45 | $0.33 (13 Analysts) |
Q3 Net Income | -$58.50 mln | ||
Q3 Gross Profit | $379.40 mln | ||
Q3 Operating Expenses | $431.20 mln | ||
Q3 Operating Income | -$51.80 mln |
Press Release: ID:nBw43qLnva
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)